Lecture on RNAi Therapeutics and Anti-tumor Therapeutics
time: 2015-07-10

Martin C. Woodle, invited by Prof. Wen Tan in InnovativeDrugs & MedicinePre-incubatorResearchCenter, visited our school at 9th July, 2015.

Themed on RGD Targeted RNAi Therapeutics for Cancer Anti-angiogenic and Anti-tumor therapeutics, he gave a lecture to students from InnovativeDrugs & MedicinePre-incubatorResearchCenter and discussed the advance of anti-tumor drug development.

Dr. Woodle has over 20 years of experience in drug delivery and therapeutic drug development, including leading the research department at Liposome Technology, Inc. (marketed by J&J) that developed PEGylated Stealth® liposomes for Doxil®, marketed by J&J, leading toxicology and formulation development at Genta that supported initiation of Genasense clinical development, and leading the Synthetic Gene Vector department within Novartis he spun off to form Intradigm Corp., which developed the first nanoparticle siRNA formulation showing preclinical efficacy.

Dr. Woodle’s experience in drug delivery and therapeutic drug development help students know more about drug research and development, and his patience and wide-knowledge benefit students to focus more deeply on the lecture and discussion.